Nociceptin Peptide Suppresses Dopamine in the Brain's Reward Center

Orphanin FQ/nociceptin — a newly discovered opioid-like peptide — suppresses dopamine release in the nucleus accumbens, suggesting an anti-reward function opposite to classical opioids.

Murphy, N P et al.·Neuroscience·1996·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00373Animal StudyModerate Evidence1996RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Orphanin FQ/nociceptin suppressed dopamine release in the nucleus accumbens, acting opposite to classical opioids which typically increase dopamine in this reward-related region.

Key Numbers

How They Did This

Intracerebroventricular injection of orphanin FQ/nociceptin in anesthetized rats with in vivo measurement of dopamine release in the nucleus accumbens.

Why This Research Matters

Discovering a natural anti-reward peptide provides new understanding of how the brain balances pleasure and motivation, with direct relevance to addiction and depression research.

The Bigger Picture

This finding helped establish nociceptin as a unique neuromodulator distinct from classical opioids, opening a new area of neuropharmacology targeting reward, pain, and mood.

What This Study Doesn't Tell Us

Animal study under anesthesia, which may alter dopamine dynamics. Direct brain injection is not a physiological route. Single brain region measured.

Questions This Raises

  • ?Could nociceptin receptor agonists be developed to reduce drug craving in addiction?
  • ?Does nociceptin dysfunction contribute to depression or anhedonia?

Trust & Context

Key Stat:
Anti-reward peptide discovered Nociceptin suppressed dopamine release in the nucleus accumbens — the opposite of what classical opioids do
Evidence Grade:
Preliminary animal evidence under anesthesia. Important mechanistic finding but physiological relevance needs confirmation in awake animals.
Study Age:
Published in 1996, shortly after nociceptin's discovery. Subsequent research has confirmed its role in modulating reward and aversion.
Original Title:
Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.
Published In:
Neuroscience, 75(1), 1-4 (1996)
Database ID:
RPEP-00373

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is nociceptin/orphanin FQ?

Nociceptin is a 17-amino-acid peptide that looks like an opioid but acts on its own unique receptor (ORL-1/NOP). Despite structural similarity to dynorphin, it has distinct and sometimes opposite effects to classical opioid peptides.

Why is dopamine suppression in the reward center significant?

The nucleus accumbens is the brain's reward hub — dopamine there drives feelings of pleasure and motivation. A natural peptide that suppresses this dopamine provides the brain with an 'anti-reward' brake, potentially helping prevent excessive reward-seeking behavior.

Read More on RethinkPeptides

Cite This Study

RPEP-00373·https://rethinkpeptides.com/research/RPEP-00373

APA

Murphy, N P; Ly, H T; Maidment, N T. (1996). Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.. Neuroscience, 75(1), 1-4.

MLA

Murphy, N P, et al. "Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.." Neuroscience, 1996.

RethinkPeptides

RethinkPeptides Research Database. "Intracerebroventricular orphanin FQ/nociceptin suppresses do..." RPEP-00373. Retrieved from https://rethinkpeptides.com/research/murphy-1996-intracerebroventricular-orphanin-fqnociceptin-suppresses

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.